Marie Thibault
Stock Analyst at BTIG
(3.43)
# 932
Out of 5,150 analysts
115
Total ratings
46.85%
Success rate
5.03%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $9.23 | +105.85% | 5 | Feb 26, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $72.90 | +16.60% | 10 | Feb 25, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $242.89 | +56.45% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $175.37 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $30.99 | +74.25% | 8 | Feb 18, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $3.53 | +324.93% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $85.22 | +20.86% | 3 | Feb 11, 2026 | |
| BSX Boston Scientific | Reiterates: Buy | $110 | $72.21 | +52.33% | 16 | Feb 9, 2026 | |
| EMBC Embecta | Reiterates: Buy | $25 | $9.61 | +160.15% | 4 | Feb 6, 2026 | |
| HAE Haemonetics | Reiterates: Buy | $88 | $64.67 | +36.08% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.52 | +282.56% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $17.77 | +68.82% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $113.10 | +23.78% | 15 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $22.29 | +43.56% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $127.95 | +68.03% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.56 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $71.14 | -8.63% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.87 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.33 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.87 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $383.47 | -98.44% | 1 | Apr 9, 2020 |
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $9.23
Upside: +105.85%
DexCom
Feb 25, 2026
Reiterates: Buy
Price Target: $85
Current: $72.90
Upside: +16.60%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $242.89
Upside: +56.45%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $175.37
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $30.99
Upside: +74.25%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.53
Upside: +324.93%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $85.22
Upside: +20.86%
Boston Scientific
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $72.21
Upside: +52.33%
Embecta
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $9.61
Upside: +160.15%
Haemonetics
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $64.67
Upside: +36.08%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.52
Upside: +282.56%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $17.77
Upside: +68.82%
Jan 23, 2026
Maintains: Buy
Price Target: $145 → $140
Current: $113.10
Upside: +23.78%
Nov 18, 2025
Initiates: Buy
Price Target: $32
Current: $22.29
Upside: +43.56%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $127.95
Upside: +68.03%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.56
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $71.14
Upside: -8.63%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.87
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.87
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $383.47
Upside: -98.44%